Vaccine drug developer AstraZeneca 'seeks merger with Covid-19 treatment firm Gilead'

AstraZeneca has approached rival drugmaker Gilead Sciences about a potential merger, according to sources, in what would be the biggest health-care deal on record.

The UK-based firm contacted Gilead last month about a possible tie-up but AstraZeneca didn’t specify terms for any transaction.